Switch theme
Sign up to access all valuation multiples
Oxurion NV is a clinical-stage biopharmaceutical company developing next-generation standard-of-care ophthalmic therapies, which are designed to improve and preserve vision in patients with retinal disorders including Geographic Atrophy (GA). The Group’s research and development facilities are located in Belgium. The Company is engaged in the development of drugs to treat blindness diseases.
2006
20
LTM Revenue n/a
LTM EBITDA n/a
$13.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Oxurion has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Oxurion achieved revenue of $0.3M and an EBITDA of -$19.9M.
Oxurion expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oxurion valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.6M | $0.3M | XXX | XXX | XXX |
| Gross Profit | $0.6M | $0.1M | XXX | XXX | XXX |
| Gross Margin | 87% | 31% | XXX | XXX | XXX |
| EBITDA | -$32.6M | -$19.9M | XXX | XXX | XXX |
| EBITDA Margin | -5094% | -7054% | XXX | XXX | XXX |
| Net Profit | -$31.3M | -$34.0M | XXX | XXX | XXX |
| Net Margin | -4901% | -12048% | XXX | XXX | XXX |
| Net Debt | $2.2M | $3.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Oxurion's stock price is EUR 0 (or $0).
Oxurion has current market cap of EUR 0.5M (or $0.5M), and EV of EUR 12.3M (or $13.2M).
See Oxurion trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13.2M | $0.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Oxurion has market cap of $0.5M and EV of $13.2M.
Oxurion's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Oxurion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Oxurion and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $13.2M | XXX | XXX | XXX |
| EV/Revenue | 46.6x | XXX | XXX | XXX |
| EV/EBITDA | -0.7x | XXX | XXX | XXX |
| P/E | -0.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpOxurion's NTM/LTM revenue growth is n/a
Oxurion's revenue per employee for the last fiscal year averaged $14K, while opex per employee averaged $0.6M for the same period.
Over next 12 months, Oxurion's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Oxurion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Oxurion and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -56% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -7054% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -39% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $14K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | -54% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1073% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3797% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 4595% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oxurion acquired XXX companies to date.
Last acquisition by Oxurion was XXXXXXXX, XXXXX XXXXX XXXXXX . Oxurion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Oxurion founded? | Oxurion was founded in 2006. |
| Where is Oxurion headquartered? | Oxurion is headquartered in Belgium. |
| How many employees does Oxurion have? | As of today, Oxurion has 20 employees. |
| Who is the CEO of Oxurion? | Oxurion's CEO is Mr. Pascal Ghoson. |
| Is Oxurion publicy listed? | Yes, Oxurion is a public company listed on BRU. |
| What is the stock symbol of Oxurion? | Oxurion trades under OXUR ticker. |
| When did Oxurion go public? | Oxurion went public in 2006. |
| Who are competitors of Oxurion? | Similar companies to Oxurion include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Oxurion? | Oxurion's current market cap is $0.5M |
| What is the current revenue growth of Oxurion? | Oxurion revenue growth between 2023 and 2024 was -56%. |
| Is Oxurion profitable? | Yes, Oxurion is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
